• In recent days, Option Care Health has drawn attention as Goldman Sachs initiated coverage with a Neutral rating while Bank of America moved to a more cautious stance, even as billionaire investor Stanley Druckenmiller highlighted the company as a long-term healthcare pick focused on home and outpatient infusion therapy.
• Together, these views underscore a tension between the long-term appeal of home-based infusion care and near-term pressures from tougher insurance approvals, therapy disruptions, and rising competition.
• With that in mind, we’ll examine how heightened near-term earnings uncertainty may reshape Option Care Health’s previously optimistic investment narrative.

Uncover the next big thing with 25 elite penny stocks that balance risk and reward.

Option Care Health Investment Narrative Recap

To own Option Care Health, you have to believe in the shift toward home and outpatient infusion care and the company’s ability to translate that trend into consistent earnings, despite payer pushback and therapy mix changes. The recent Goldman Sachs Neutral rating and Bank of America downgrade both highlight the same near term catalyst and risk: how quickly management can stabilize earnings after weaker Q1 2026 results and a lower full year revenue outlook.

Among recent updates, the Q1 2026 earnings release and reduced 2026 revenue guidance to US$5.675 billion to US$5.775 billion are most relevant. They brought the market’s focus squarely onto slowing growth, therapy specific disruption in the chronic portfolio and tougher insurance approvals, which sit uncomfortably beside the longer term optimism expressed by Stanley Druckenmiller and others around home based infusion demand.

Yet beneath the appeal of home infusion growth, investors should be aware of how tighter insurance authorizations and changing therapy mix could...

Option Care Health's narrative projects $6.8 billion revenue and $298.2 million earnings by 2029. This requires 6.5% yearly revenue growth and about a $92 million earnings increase from $206.2 million today.

Uncover how Option Care Health's forecasts yield a $29.18 fair value, a 36% upside to its current price.

Exploring Other Perspectives

The most bearish analysts were already modeling slower revenue growth of about 5.9 percent a year and 2029 earnings of roughly US$295.7 million, so this mix of cautious Wall Street views and chronic therapy headwinds could either validate their concerns or force a rethink of both bullish and bearish narratives as new data comes in.

Explore 2 other fair value estimates on Option Care Health - why the stock might be worth just $24.78!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Option Care Health research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Option Care Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Option Care Health's overall financial health at a glance.

Curious About Other Options?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Outshine the giants: these 14 early-stage AI stocks could fund your retirement.
• Find 48 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.